Cell Biotech Co. Ltd (049960) - Total Liabilities

Latest as of September 2025: ₩7.46 Billion KRW ≈ $5.06 Million USD

Based on the latest financial reports, Cell Biotech Co. Ltd (049960) has total liabilities worth ₩7.46 Billion KRW (≈ $5.06 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cell Biotech Co. Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Cell Biotech Co. Ltd - Total Liabilities Trend (2011–2024)

This chart illustrates how Cell Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Cell Biotech Co. Ltd asset portfolio.

Cell Biotech Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Cell Biotech Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Thryv Holdings Inc NASDAQ:THRY	USA	$480.72 Million
Hennessy Ad NASDAQ:HNNA	USA	$60.52 Million
MediciNova Inc NASDAQ:MNOV	USA	$3.61 Million
Ybox Real Estate Ltd TA:YBOX	Israel	ILA999.76 Million
Columbus Acquisition Corp Ordinary Shares NASDAQ:COLA	USA	$106.25K
Gopeng Bhd KLSE:2135	Malaysia	RM243.67 Million
Kalleback Property Invest AB ST:KAPIAB	Sweden	Skr668.05 Million
Holland Colours NV AS:HOLCO	Netherlands	€14.97 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Cell Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Cell Biotech Co. Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	13.72	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cell Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cell Biotech Co. Ltd (2011–2024)

The table below shows the annual total liabilities of Cell Biotech Co. Ltd from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩6.23 Billion ≈ $4.22 Million	+8.23%
2023-12-31	₩5.76 Billion ≈ $3.90 Million	-25.70%
2022-12-31	₩7.75 Billion ≈ $5.25 Million	+25.16%
2021-12-31	₩6.19 Billion ≈ $4.19 Million	+16.42%
2020-12-31	₩5.32 Billion ≈ $3.60 Million	+13.09%
2019-12-31	₩4.70 Billion ≈ $3.19 Million	-26.80%
2018-12-31	₩6.42 Billion ≈ $4.35 Million	+2.26%
2017-12-31	₩6.28 Billion ≈ $4.26 Million	-1.51%
2016-12-31	₩6.38 Billion ≈ $4.32 Million	+2.67%
2015-12-31	₩6.21 Billion ≈ $4.21 Million	+18.44%
2014-12-31	₩5.24 Billion ≈ $3.55 Million	+43.75%
2013-12-31	₩3.65 Billion ≈ $2.47 Million	-6.06%
2012-12-31	₩3.88 Billion ≈ $2.63 Million	-22.03%
2011-12-31	₩4.98 Billion ≈ $3.37 Million	--

About Cell Biotech Co. Ltd

KQ:049960 Korea Biotechnology & Medical Research

Market Cap

$80.57 Million

₩118.89 Billion KRW

Market Cap Rank

#20139 Global

#1072 in Korea

Share Price

₩15400.00

Change (1 day)

+0.06%

52-Week Range

₩11500.00 - ₩18110.00

All Time High

₩56579.38